Non-Sponsored
Non-Sponsored
Advertisement
Charles Gaulin, MBBSMantle Cell Lymphoma | July 8, 2025
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Read More
Melissa BadamoAcute Lymphoblastic Leukemia | July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Nichole TuckerMyeloma | July 3, 2025
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Nichole TuckerNon-Sponsored | July 3, 2025
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
Andrew MorenoHodgkin Lymphoma | July 2, 2025
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
Melissa BadamoWaldenstrom's Macroglobulinemia | July 2, 2025
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
Andrew MorenoMyelodysplastic Syndromes | July 2, 2025
No new safety signals were observed in this phase 3 trial which compared the combination with placebo plus azacitidine.
Melissa BadamoAcute Myeloid Leukemia | July 1, 2025
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Matthew Davids, MD, MMScChronic Lymphocytic Leukemia | June 27, 2025
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
Nichole TuckerFollicular Lymphoma | June 27, 2025
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Anthony S. Stein, MDMeeting News | June 27, 2025
TAG shows promise as frontline therapy in BPDCN, minimizing toxicity and supporting safer stem cell transplant.
Melissa BadamoFollicular Lymphoma | June 25, 2025
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
Melissa BadamoAcute Myeloid Leukemia | June 24, 2025
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Rahul Banerjee, MD, FACPMyeloma | June 24, 2025
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Nichole TuckerPrint | June 24, 2025
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
Melissa BadamoAcute Myeloid Leukemia | June 24, 2025
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
Sara KarlovitchNon-Sponsored | June 25, 2025
FDA roadmap explores AI to predict toxicity, cut animal testing, and speed drug development with chip tech.
Christos Evangelou, PhDPrint | June 24, 2025
The advent of AI technologies such as machine learning has opened new avenues for predicting adverse drug reactions.
Izzah NawazMyeloma | June 23, 2025
A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.
Andrew MorenoMyelofibrosis | June 25, 2025
The agent, nuvisertib, previously received Orphan Drug Designation from the FDA for this indication in May 2022.
Advertisement
Advertisement